H.C. Wainwright downgraded SpringWorks Therapeutics (SWTX) to Neutral from Buy with a price target of $47, down from $74, citing the takeover agreement with Merck KGaA (MKGAY). The firm does not expect any rival bidders to emerge.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics downgraded to Hold from Buy at TD Cowen
- Hold Rating on Merck KGaA’s Acquisition of Springworks: Strategic Fit with Valuation Concerns
- SpringWorks Therapeutics downgraded to Neutral from Buy at Guggenheim
- Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz
- Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’